An oncolytic virus is able to modify the tumor microenvironment to make it more susceptible to concurrent ICI.23 There was evidence that T-VEC intratumoral administration produced a systemic increase in circulating CD4+ and CD8+ T cells and increased CD8+ T cell infiltration into tumors. The gene discussed is CD4; the disease is neoplasm.